Bioceptive, a women’s health startup company in New Orleans, is getting a $250,000 grant to test one of its contraception devices at clinics in the developing world.

Bioceptive, based in the New Orleans BioInnovation Center, is among 17 grant recipients out of more than 750 submissions for funding from Saving Lives at Birth.

Bioceptive is developing several women’s health medical devices, including a reusable, easy-to-use intrauterine device, or IUD inserter. Although IUDs are one of the most effective forms of long-term contraception, they are often unavailable in the developing world due to the complexity of a multi-tool insertion procedure, the company said.

Bioceptive will use its grant to fund a validation trial of its simpler, low-cost inserter device in South Asia before scaling up to reach clinics around the world.

“Numerous studies have shown that improved access to family planning and control over birth spacing can save the lives of hundreds of thousands of women and infants,” said Bioceptive Chief Operating Officer Shuchi ‘SK’ Khurana. “This award and the relationships developed with international partners of the Saving Lives at Birth program over the last three years will be instrumental in helping us bring our product to women in need in low-resource settings around the world.”

Saving Lives at Birth is a partnership of the U.S. Agency for International Development; the Government of Norway; the Bill & Melinda Gates Foundation; government-funded Grand Challenges Canada; the U.K’s Department for International Development; and the Korean International Cooperation Agency. Since 2011, the coalition has provided more than $47 million toward more than 80 groundbreaking and scalable tools and approaches to reduce infant and maternal mortality.

Bioceptive also is receiving consulting support from McCann Global Health after winning first place in the DevelopmentXChange Pitch Competition at the Saving Lives at Birth partnership’s annual conference in Washington, D.C.